ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0265

Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care
Abstract Number: 0266

Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Abstract Number: 0267

IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis
Abstract Number: 0268

Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study
Abstract Number: 0269

Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Abstract Number: 0270

Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Abstract Number: 0271

Intercritical Gout Represents a Systemic Inflammatory State
Abstract Number: 0272

Calcifications of the Transverse Ligament of the Atlas in Patients Diagnosed with Calciumpyrophosphate Crystal Arthritis – a Retrospective Observational Study
Abstract Number: 0273

Barriers and Facilitators for Outpatient Follow-Up After an Acute Gout Flare: A Qualitative Research Study
Abstract Number: 0274

Cost-effectiveness of Low Dose Colchicine Prophylaxis When Starting Allopurinol Using the “Start-Low Go-Slow” Approach for Gout
Abstract Number: 0275

Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation
Abstract Number: 0276

Exploring the Prevalence of Crowned Dens Syndrome in a Polymyalgia Rheumatica Veterans Affairs Patient Cohort
Abstract Number: 0277

Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation
Abstract Number: 0278

Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Abstract Number: 0279

Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].